Nuwellis Expands Pediatric Ultrafiltration Program in Florida

Nuwellis, Inc., a medical technology company, has launched a new pediatric ultrafiltration program utilizing its Aquadex SmartFlow System at one of the largest hospital networks in Florida, aiming to improve health outcomes for pediatric patients with fluid overload by providing a precise and customizable therapy option. This expansion marks a significant milestone for Nuwellis, demonstrating its commitment to advancing innovative medical technologies and improving patient care across all age groups. This description focuses on the primary topic (launch of pediatric ultrafiltration program), main entities (Nuwellis, Inc. and the hospital network), context (Florida), significant actions (launch of program), and objective details (Aquadex SmartFlow System and its features) that will guide the AI in creating an accurate visual representation of the article's content.

author-image
Bijay Laxmi
New Update
Nuwellis Expands Pediatric Ultrafiltration Program in Florida

Nuwellis Expands Pediatric Ultrafiltration Program in Florida

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, has announced the launch of a new pediatric ultrafiltration program utilizing its Aquadex SmartFlow System at one of the largest integrated delivery networks (IDN) in Florida. This program marks an expansion by the network to offer ultrafiltration to its pediatric patients, in addition to its current heart failure and critical care patients.

Why this matters: The expansion of ultrafiltration therapy to pediatric patients has the potential to significantly improve health outcomes for this vulnerable population, reducing the risk of complications and improving quality of life. Additionally, this development may pave the way for further innovations in medical technology, driving progress in the treatment of fluid overload and related conditions.

The program is an expansion of the existing collaboration between Nuwellis and the hospital network, which currently uses Nuwellis' technology in seven hospitals for adult cardiac and critical care. The Aquadex SmartFlow System is cleared by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients weighing 20 kg or more. The system is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics.

"We are excited to collaborate on the expansion of the pediatric Aquadex ultrafiltration program at this leading hospital network," said Nestor Jaramillo, Jr., President and Chief Executive Officer at Nuwellis. "The expansion of Aquadex into pediatric care underscores the success of this therapy and the commitment of the network to advance ultrafiltration therapy and improve patient outcomes across all age groups."

The Aquadex system's built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients' needs. A customizable fluid removal rate is particularly important for pediatric patients who have a small amount of blood in their bodies. The launch of the pediatric program is part of Nuwellis' strategy to grow its pediatric customer category.

Nuwellis is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy. The company is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. The Aquadex system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

The expansion of the Aquadex SmartFlow System into pediatric care at the One of the Largest Hospital Networks in Florida marks a significant milestone for Nuwellis. By offering a precise and customizable ultrafiltration therapy option for fluid overloaded pediatric patients, the program aims to improve outcomes for this vulnerable patient population. The collaboration between Nuwellis and the hospital network underscores their shared commitment to advancing innovative medical technologies and providing the best possible care for patients of all ages.

Key Takeaways

  • Nuwellis launches pediatric ultrafiltration program at a major Florida hospital network.
  • Aquadex SmartFlow System treats fluid overload in pediatric patients weighing 20 kg or more.
  • System provides customizable fluid removal rate and real-time hematocrit monitoring.
  • Expansion aims to improve health outcomes and quality of life for pediatric patients.
  • Nuwellis grows pediatric customer category with this new program.